Day: March 10, 2025

NETCLASS TECHNOLOGY INC. Strengthens Market Position in Asia with Strategic Acquisition of Japan-based CreateSolutions Co., Ltd.

Written by Customer Service on March 10, 2025. Posted in Mergers And Acquisitions.

SHANGHAI and HONG KONG, March 10, 2025 (GLOBE NEWSWIRE) — NETCLASS TECHNOLOGY INC. (the “Company” or “NETCLASS”), a leading B2B smart education IT solutions provider with offices in Shanghai, Hong Kong, and Singapore, today announced its acquisition of a 51% stake in CreateSolutions Co., Ltd. (“CreateSolutions”), a Tokyo-based software company, by investing JPY 2,550,000 to acquire 255 shares of CreateSolutions. CreateSolutions is a software company specializing in customized, high-efficiency, and sustainable technology solutions. Its services include software development, data analysis, business consulting, corporate innovation training, business process optimization, and innovative product design. The acquisition marks a significant step in NETCLASS’ strategy to expand its market across Asia. It provides the Company with a new...

Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025

Written by Customer Service on March 10, 2025. Posted in Earnings Releases And Operating Results.

PRT3789 has demonstrated clinical proof-of-concept that selectively degrading SMARCA2 is generally safe and has monotherapy anti-tumor activity in patients with SMARCA4-deficient, non-small cell lung (NSCLC), gastric and esophageal cancer PRT3789 monotherapy dose escalation enrollment is nearing completion and dose escalation in combination with docetaxel continues with plans to present additional results from both cohorts in the second half of 2025 Enrollment into the Phase 1 study of Prelude’s once daily, oral SMARCA2 degrader, PRT7732 is on track and an interim data update is anticipated in the second half of 2025 Current cash runway into second quarter of 2026 with $133.6 million in cash, cash equivalents and marketable securities as of December 31, 2024 WILMINGTON, Del., March 10, 2025 (GLOBE NEWSWIRE) — Prelude Therapeutics...

Applied Materials Increases Quarterly Cash Dividend by 15 Percent and Announces New $10 Billion Share Repurchase Authorization

Written by Customer Service on March 10, 2025. Posted in Dividend Reports And Estimates.

SANTA CLARA, Calif., March 10, 2025 (GLOBE NEWSWIRE) — Applied Materials, Inc. today announced that its Board of Directors has approved a 15-percent increase in the quarterly cash dividend, marking eight consecutive years of higher dividends. The increase results in a quarterly dividend of $0.46 per share payable on June 12, 2025 to shareholders of record as of May 22, 2025. The Board also approved a new share repurchase authorization enabling Applied to buy back an additional $10 billion of its shares over time. This supplements the previous authorization which had approximately $7.6 billion remaining at the end of the first quarter of fiscal 2025. “Over the past 10 fiscal years, Applied Materials has distributed nearly 90 percent of free cash flow to shareholders,” said Brice Hill, Senior Vice President and CFO. “The dividend...

Polyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T Platform

Written by Customer Service on March 10, 2025. Posted in Public Companies.

Raanana, Israel, March 10, 2025 (GLOBE NEWSWIRE) — Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced today the initiation of preclinical studies for intranasal Naloxone, a life-saving opioid overdose treatment. The study will be conducted in collaboration with Professor Fabio Sonvico, Associate Professor at the Department of Food and Drug of the University of Parma (Italy) a leading expert in the development of intranasal and pulmonary drug delivery solutions and a member of the Company’s Scientific Advisory Board. These preclinical studies mark a step forward in evaluating Polyrizon’s Trap and Target™ (T&T) platform for the intranasal administration of Naloxone, an opioid...

Bird Joint Venture Signs Project Alliance Agreement for East Harbour Transit Hub

Written by Customer Service on March 10, 2025. Posted in Public Companies.

MISSISSAUGA, Ontario, March 10, 2025 (GLOBE NEWSWIRE) — Bird Construction Inc. (TSX: BDT) is pleased to announce that Rail Connect Partners, its 50/50 joint venture with AtkinsRéalis, has finalized and signed a Project Alliance Agreement with Metrolinx to deliver the East Harbour Transit Hub, that will strengthen transit options for the City of Toronto. The execution phase of the project includes completion of the rail corridor and bridge widening over an important thoroughfare, which will continue to be undertaken in planned phases to keep GO Transit services running with minimal impact. The execution phase will also include the commencement of the station works and associated infrastructure and future road extension to facilitate a future streetcar connection. “The Metrolinx team is proud to work with partners in government...

SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea

Written by Customer Service on March 10, 2025. Posted in Public Companies.

TEL AVIV, Israel, March 10, 2025 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that its collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) has led to the publication of a patent application by the South Korean Intellectual Property Office (“KIPO”). The patent application relates to a combination treatment using Clearmind’s 5-methoxy-2-aminoindane (“MEAI”) and SciSparc’s Palmitoylethanolamide (“PEA”) for the treatment of cocaine addiction. The patent is based on preclinical trial results led by Professor Gal Yadid and his team at the Gonda Multidisciplinary Brain Research Center at Bar-Ilan University in Israel....

OptimizeRx Corporation Appoints Stephen Silvestro as Chief Executive Officer

Written by Customer Service on March 10, 2025. Posted in Public Companies.

Silvestro has a demonstrated record of accelerating revenue growth, expanding brand relevance, and building a market-leading team WALTHAM, Mass., March 10, 2025 (GLOBE NEWSWIRE) — OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced it has appointed Steve Silvestro as the Company’s new Chief Executive Officer, effective March 10, 2025. Mr. Silvestro brings to OptimizeRx more than 20 years of experience in building and managing health technology and services companies, and has served as an executive at OptimizeRx since joining the Company in 2019. His career includes strategic development, sales leadership, technology and product innovation, and M&A within a variety...

Man Group PLC : Form 8.3 – Dalata Hotel Group

Written by Customer Service on March 10, 2025. Posted in Mergers And Acquisitions.

Ap27 FORM 8.3 IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVERRULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION(a) Full name of discloser Man Group PLC(b) Owner or controller of interests and short positions disclosed, if different from 1(a) The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant securities this form relates Use a separate form for each offeror/offeree Dalata Hotel Group plc(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1) (e) Date position held/dealing...

Cheer Holding Reports Full Year 2024 Financial Results

Written by Customer Service on March 10, 2025. Posted in Earnings Releases And Operating Results.

BEIJING, March 10, 2025 (GLOBE NEWSWIRE) — Cheer Holding, Inc. (NASDAQ: CHR) (“Cheer Holding,” or the “Company”), a leading provider of advanced mobile internet infrastructure and platform services, today announced its financial results for the full year ended December 31, 2024. Operating Highlights For The Year Ended December 31, 2024 Total downloads of CHEERS Apps were approximately 523.3 million as of December 31, 2024, representing a growth of 10.4% from December 31, 2023. Specifically: CHEERS VideoAccumulated downloads of CHEERS Video grew by 6.3% YoY to approximately 436 million as of December 31, 2024. Monthly Active Users of CHEERS Video increased by 4.4% to approximately 52.3 million. Daily Time Spent for using CHEERS Video during 2024 was approximately 60 minutes.CHEERS e-MallAccumulated downloads of CHEERS e-Mall...

Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results

Written by Customer Service on March 10, 2025. Posted in Earnings Releases And Operating Results.

Initiated Phase 1 Single Ascending Dose Trial of DT-216P2 in Healthy Volunteers; Friedreich Ataxia (FA) Patient Dosing to Begin in mid-2025 Dosing Complete in DT-168 Phase 1 Healthy Volunteer Trial, with Data on Track for the First Half of 2025; Enrollment Target Achieved in Fuchs Endothelial Corneal Dystrophy (FECD) Observational Study Selection of Development Candidate for Myotonic Dystrophy Type-1 (DM1) Expected in 2025 Well-Capitalized with Cash and Securities of $245.5 Million to Fund Operations Through Up to Four Potential Clinical Proof-of-Concept Data Sets CARLSBAD, Calif., March 10, 2025 (GLOBE NEWSWIRE) — Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced progress across its portfolio of GeneTAC® candidates and...

Day: March 10, 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals